Back to Journals » Psoriasis: Targets and Therapy » Volume 2
![](https://www.dovepress.com/cr_data/cache/journal_image/121/cope/thumb_100_1000_100.jpg)
Psoriasis: Targets and Therapy
ISSN: 2230-326X
- View all (141)
- Volume 14, 2024 (8)
- Volume 13, 2023 (7)
- Volume 12, 2022 (22)
- Volume 11, 2021 (14)
- Volume 10, 2020 (8)
- Volume 9, 2019 (13)
- Volume 8, 2018 (12)
- Volume 7, 2017 (9)
- Volume 6, 2016 (15)
- Volume 5, 2015 (13)
- Volume 4, 2014 (5)
- Volume 3, 2013 (4)
- Volume 2, 2012 (10)
- Volume 1, 2011 (1)
Archive: Volume 2, 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Management of guttate psoriasis in patients with associated streptococcal infection
Karabudak Abuaf O, Dogan B
Psoriasis: Targets and Therapy 2012, 2:89-94
Published Date: 20 November 2012
![Noteworthy comment: This is a very large retrospective analysis of safety issues of topical vitamin D analogues in psoriasis therapy. Risk factors for the development of a treatment related hypercacliaemia have been identified. Available data suggest calcipotriol as a safe alternative to maxacalcitol or tacalcitol in those patients at risk.](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Safety profiles of topical vitamin D3 in psoriasis patients: a retrospective large-scale study
Yamamoto A, Furuhashi T, Matsumoto K, Morita A
Psoriasis: Targets and Therapy 2012, 2:81-88
Published Date: 15 November 2012
![Noteworthy comment: The study investigates in a detailed fashion the role of lipid pathway disturbances in psoriasis.](assets/img/article_icons/noteworthy.png)
![Video](assets/img/article_icons/video.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Lipid profile in psoriasis patients
![](assets/img/youtube_social_icon_dark.png)
![](http://img.youtube.com/vi/SiC_BotU2m8/1.jpg)
Bhat RM, Pinto HP
Psoriasis: Targets and Therapy 2012, 2:77-80
Published Date: 9 November 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Psoriasis: epidemiology, natural history, and differential diagnosis
Basko-Plluska JL, Petronic-Rosic V
Psoriasis: Targets and Therapy 2012, 2:67-76
Published Date: 11 September 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Biomarkers in the pathogenesis, diagnosis, and treatment of psoriasis
Molteni S, Reali E
Psoriasis: Targets and Therapy 2012, 2:55-66
Published Date: 4 September 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
The management of psoriasis through diet
Duarte G, Barbosa LO, Rosa ME
Psoriasis: Targets and Therapy 2012, 2:45-53
Published Date: 7 August 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Biologics in the treatment of psoriasis and emerging new therapies in the pipeline
Levy LL, Solomon SM, Emer JJ
Psoriasis: Targets and Therapy 2012, 2:29-43
Published Date: 18 June 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Plaque psoriasis in children and adolescents – the role of etanercept
Ricceri F, Tripo L, Pescitelli L, Prignano F
Psoriasis: Targets and Therapy 2012, 2:25-28
Published Date: 11 June 2012
![Noteworthy comment: Very complete discussion of various tools to measure quality of life issues in patients with psoriasis.](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Quality of life issues and measurement in patients with psoriasis
Tan X, Feldman SR, Balkrishnan R
Psoriasis: Targets and Therapy 2012, 2:13-23
Published Date: 21 February 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Psoriasis and cardiovascular disease: epidemiology, mechanisms, and clinical implications
Pearson KC, Armstrong AW
Psoriasis: Targets and Therapy 2012, 2:1-11
Published Date: 13 January 2012